Victoria Elizabeth Demby

Dr. Demby is Senior Vice President of Global Regulatory Affairs (GRA) at Adlai Nortye USA Inc. Prior to that she was an Executive Director and Team Lead in the GRA, Oncology department at GlaxoSmithKline (GSK). She received her B.S. in Biochemistry from the University of Vermont, and her Ph.D. from the University of Kansas. Vicki is an experienced regulatory affairs professional holding regulatory roles of increasing responsibility in various therapeutic areas. Before joining GSK, she was a Global Regulatory Lead at Merck responsible for several Keytruda® indications; obtaining approvals for unresectable malignant melanoma in Japan; the first approval in China, and the first adjuvant indication in US, EU, AU, and Japan; and accelerated approval of Merkel cell carcinoma in the US. She has also taught several lectures at University of Maryland, Baltimore for their MS in Regulatory Sciences program.